Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) rose 7.1% during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as $163.00 and last traded at $167.0560. 117,062 shares changed hands during trading, a decline of 38% from the average session volume of 188,958 shares. The stock had previously closed at $155.94.
The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19.
Latest Belite Bio News
Investors following BLTE have been watching these news items:
- Positive Sentiment: Leerink Partners raised its price target to $215 from $185 and reiterated an “outperform” rating, signaling confidence in Belite Bio’s outlook. TickerReport article
- Positive Sentiment: Belite reported a third-quarter loss of $0.60 per share, narrower than analysts’ expected loss of $0.79, providing a modest earnings beat. Quarterly earnings results
- Negative Sentiment: The company recorded a $30.3 million quarterly net loss, underscoring the costs and risks of developing its drug candidate before potential commercialization. Quarterly loss report
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Belite Bio
Insider Buying and Selling at Belite Bio
In other Belite Bio news, CEO Yu-Hsin Lin sold 74,435 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $187.71, for a total value of $13,972,193.85. Following the completion of the transaction, the chief executive officer directly owned 96,134 shares in the company, valued at approximately $18,045,313.14. The trade was a 43.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Hendrik Scholl sold 500 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $165.32, for a total transaction of $82,660.00. Following the sale, the insider directly owned 14,500 shares of the company’s stock, valued at approximately $2,397,140. The trade was a 3.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 168,330 shares of company stock worth $31,969,118 over the last quarter. Insiders own 13.29% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP bought a new position in shares of Belite Bio during the 3rd quarter worth approximately $15,282,000. State Street Corp boosted its stake in Belite Bio by 6.9% in the third quarter. State Street Corp now owns 34,044 shares of the company’s stock valued at $5,781,000 after acquiring an additional 2,196 shares in the last quarter. Alberta Investment Management Corp acquired a new stake in Belite Bio in the third quarter valued at approximately $4,076,000. Candriam S.C.A. acquired a new stake in Belite Bio in the third quarter valued at approximately $10,711,000. Finally, Vise Technologies Inc. acquired a new stake in Belite Bio in the third quarter valued at approximately $217,000. Hedge funds and other institutional investors own 0.53% of the company’s stock.
Belite Bio Price Performance
The company’s fifty day simple moving average is $160.88 and its 200-day simple moving average is $160.24. The firm has a market capitalization of $6.62 billion, a PE ratio of -60.20 and a beta of -1.19.
Belite Bio Company Profile
Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.
Featured Articles
- Five stocks we like better than Belite Bio
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
